NCT03023722 - Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

August 6, 2019

Study Completion Date

December 11, 2019

Conditions

Pancreatic Cancer

Interventions

DRUG

anetumab ravtansine

Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle

Trial Locations (3)

Vanderbilt-Ingram Cancer Center, Nashville

Yale Cancer Center, New Haven

Rutgers Cancer Institute of New Jersey, New Brunswick